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Alzheimer’s disease (AD) currently presents one of the biggest healthcare issues in the developed countries. There is no effective
treatment capable of slowing down disease progression. In recent years the main focus of research on novel pharmacotherapies
was based on the amyloidogenic hypothesis of AD, which posits that the beta amyloid (A𝛽) peptide is chiefly responsible for
cognitive impairment and neuronal death. The goal of such treatments is (a) to reduce A𝛽 production through the inhibition of
𝛽 and 𝛾 secretase enzymes and (b) to promote dissolution of existing cerebral A𝛽 plaques. However, this approach has proven
to be only modestly effective. Recent studies suggest an alternative strategy centred on the inhibition of the downstream A𝛽
signalling, particularly at the synapse. A𝛽 oligomers may cause aberrant N-methyl-D-aspartate receptor (NMDAR) activation
postsynaptically by forming complexes with the cell-surface prion protein (PrPC). PrPC is enriched at the neuronal postsynaptic
density, where it interacts with Fyn tyrosine kinase. Fyn activation occurs when A𝛽 is bound to PrPC-Fyn complex. Fyn causes
tyrosine phosphorylation of the NR2B subunit of metabotropic glutamate receptor 5 (mGluR5). Fyn kinase blockers masitinib and
saracatinib have proven to be efficacious in treating AD symptoms in experimental mouse models of the disease.
1. Introduction
Alzheimer’s disease (AD) is currently incurable neurodegen-
erative condition which is highly prevalent in old age [1–3]. It
was first described in 1906 by Alois Alzheimer, who analysed
brain tissue from a patient who had died from an unknown
mental illness. According to the Alzheimer’s Association, 13%
of people over 65 suffer from this disease in developed coun-
tries, where it is the fifth leading cause of death in patients
at this age. According to the World Health Organization
(WHO) estimates, the overall projected prevalence in global
population will quadruple in the next decades, reaching 114
million patients by 2050 [2]. Apart from having a great social
impact, this would clearly lead to increased economic burden
to healthcare systems worldwide [1–3].
AD is classified according to the age of onset and whether
it is developed spontaneously or as a result of genetic muta-
tions. Familial AD (FAD) is an early-onset (sometimes as
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Table 1
Activity Compound Clinical trial
Inhibitors of 𝛽-secretase
(i) E2609
(ii) MK-8931
(iii) LY2886721
(i) NCT01600859
(ii) NCT01739348
(iii) NCT01807026 and NCT01561430
Inhibitors and modulators
of 𝛾-secretase
(i) Semagacestat (LY450139)
(ii) Avagacestat
(i) NCT00762411, NCT01035138, and
NCT00762411
(ii) NCT00810147, NCT00890890, NCT00810147,
NCT01079819
Selective 𝛾-secretase
modulators (SGSM)
(i) Ibuprofen, sulindac, indomethacin, and
R-flurbiprofen (Tarenflurbil)
(ii) NIC5-15
NCT00322036, NCT00105547
Nonsteroidal inhibitory of
cyclooxygenase activity
(NSAIDs)
CHF5074 NCT01203384, NCT01303744, NCT00954252
Inhibitors of A𝛽
aggregation
(i) Glycosaminoglycans 3-amino acid,
1-propanesulfonic synthetic (3APS, Alzhemed,
tramiprosate)
(ii) Colostrinin
(iii) Scyllo-inositol compound (ELND005)
(iv) PBT1 (clioquinol) and PBT2
Phase III in 2007
Modulation of 𝛽-amyloid
transport from the brain to
the peripheral circulation
(i) PF-0449470052
(ii) TTP4000 (NCT01548430)
(i) Phase II
(ii) Phase I (February 2013)
Active immunotherapy
(i) Anti-A𝛽42 vaccine (AN1792)
(ii) CAD 106
(iii) ACC-001
(iv) ACI-24, MER5101 and AF205
(v) Bapineuzumab, solanezumab
(vi) Gantenerumab
(vii) Crenezumab (MABT5102A)
(viii) Ponezumab (PF-04360365)
(ix) MABT5102A, GSK933776A, NI-101,
SAR-228810 and BAN-2401
(x) Gammagard
(i) Phase II
(ii) NCT01284387, NCT00479557 and phase II
NCT01227564 (rejected)
(iii) Preclinical
(iv) NCT01127633, NCT02008357 and
NCT01900665 phase III (2012)
(v) NCT01760005, NCT02051608 and
NCT01224106 phase III
(vi) NCT01343966, NCT01998841 phase II (April
2013)
(vii) Phase I
(viii) NCT00818662
early as 40 years of age) disease, which is caused by hereditary
mutations and represents approximately 2% of diagnosed
cases. The vast majority of patients suffer from the sporadic
AD, which is subdivided into early- and late-onset forms. If
identified in individuals under 65 years of age, early-onset
diagnosis is given (3–5%prevalence), with the rest of the cases
referred to as a late-onset AD (95–97% prevalence) [3–7]. In
FAD, mutations in genes coding for amyloid precursor pro-
tein (APP; chromosome 21), presenilin 1 (PS1; chromosome
14) and presenilin 2 (PS2; chromosome 1), serve as triggers for
beta amyloid (A𝛽) formation, particularly of the long form
of the peptide (A𝛽1-42). In case of sporadic AD, a significant
number of patients (approximately 25%) are carriers of the e4
allele of the ApoE gene (apolipoprotein E; chromosome 19), a
lipid transport protein. The exact mechanism whereby ApoE
contributes to increased A𝛽 levels is currently unknown [6–
9].
Aging is considered the principal risk factor for sporadic
AD development. Other potential risk factors including
hypertension, dyslipidemia, metabolic syndrome and dia-
betes have also been identified [10–12].
In the present paper, we discuss treatment strategies
structured according to a number of existing hypotheses
aimed at explaining the origins of AD:
(a) amyloid cascade hypothesis,
(b) cholinergic hypothesis,
(c) dendritic hypothesis,
(d) mitochondrial cascade hypothesis,
(e) metabolic hypothesis,
(f) other hypotheses (oxidative stress, neuroinflamma-
tion).
The principal targets and clinical trials of the compounds
aimed at reducingA𝛽 formation and plaques are summarized
in Table 1. Relevant data for the molecules developed in
the context of cholinergic, dendritic, mitochondrial cascade,
metabolic and other hypotheses are presented in Table 2.
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Table 2
Activity Compound Clinical trial
Inhibitors of Tau
hyperphosphorylation:
glycogen synthase kinase 3
inhibitors (GSK3𝛽)
(i) Tideglusib
(ii) NP031112
(iii) Sodium selenite (VEL015)
(i) NCT01350362 phase II
(ii) NCT00948259
(iii) ACTRN12611001200976 phase II
Inhibitors of Tau
aggregation RemberTM, TRx 0237
NCT01626391, NCT01689233, NCT01689246 and
NCT01626378
Microtubule stabilizers
(i) Paclitaxel
(ii) Epothilone D
(iii) TPI 287 (taxane)
(i) Clinical trial 2013 (interrupted)
(ii) NCT01966666
Tau-specific
immunotherapy AADvac1 vaccine
NCT01850238 and NCT02031198 phase I trial
(2013)
Anticholinesterase
inhibitors
(i) Donepezil, rivastigmine, galantamine,
(ii) Ladostigil (TV3326)
PrPC–mGluR5–Fyn
signaling
(i) Masitinib
(ii) Saracatinib (AZD0530)
(i) NCT00976118
(ii) NCT01864655 and NCT02167256
5-HT6 receptor blockage Lu-AE-58054 (SGS-518), PF-05212365 (SAM-531),SUVN-502, AVN-322, PRX-07034 Different phases of clinical trials
Antidiabetic drugs
(i) Rosiglitazone and pioglitazone
(ii) Intranasal insulin (Humulin R U-100)
(iii) Amylin and pramlintide (amylin analog)
(i) NCT00550420, NCT00348140 phase III
(ii) NCT01767909
(iii) NCT01429623 and NCT01354691 phase II
Cdk5 inhibitors Roscovitine and flavopiridol
2. The Amyloid Cascade Hypothesis
A𝛽 peptide is derived from proteolysis of APP, an integral
transmembrane protein found in different cell types, includ-
ing neurons and glial cells [1–4]. In humans, alternative
splicing produces multiple isoforms of the molecule, with
APP695 being the most abundant in the brain [3]. APP is
processed into smaller peptide fragments, one of which is
A𝛽, via cleavage by 𝛼-, 𝛽-, and 𝛾-secretase enzyme protein
complexes, which include presenilin and nicastrin molecules
[8]. Under physiological conditions, APP is catabolized by
the 𝛼-secretase to produce a soluble sAPP𝛼 fragment, which
remains in the extracellular space, and a carboxy-terminal 83-
amino acid (C83) fragment, which is anchored in the plasma
membrane [8–10]. sAPP𝛼 is involved in the regulation of neu-
ronal excitability, improves synaptic plasticity, learning, and
memory, and increases neuronal resistance to oxidative and
metabolic stresses [8]. In a neuropathological situation, APP
is first preferentially cleaved by 𝛽-secretase 1 (BACE), which
fragments APP into sAPP𝛽 and a 99-amino acid membrane-
bound fraction (C99). Additional processing of the C99
fragment by 𝛾-secretase results in the generation of either
A𝛽(1-40) or A𝛽(1-42) peptides, thought to be responsible for
senile plaque formation [8–12]. Whilst sAPP𝛼 is beneficial to
the organism, A𝛽 peptides may cause synaptic loss, decrease
neuronal plasticity, alter energymetabolism, induce oxidative
stress and mitochondrial dysfunction, and may provoke
disruptions in cellular calcium homeostasis [8, 9].
The amyloid cascade hypothesis suggests that the for-
mation, aggregation, and deposition of A𝛽 peptides, and
especially A𝛽(1-42), are a primary event in AD pathogenesis
which triggers neurotoxicity and neurodegeneration [6–8].
Excessive extracellular A𝛽 may also presumably lead to
increased Tau phosphorylation and the formation of neu-
rofibrillary tangles.Molecular genetics studies into themech-
anisms of FAD gave credence to this hypothesis, suggesting
potential novel therapeutics, such as inhibitors of 𝛽- and 𝛾-
secretase or enhancers of 𝛼-secretase activity. However, in
cases of sporadicAD,whereA𝛽 generation does not appear to
have a clear genetic basis, amyloid cascade hypothesis cannot
fully explain the root causes of the disease [11–13].
2.1. Imbalance in the Generation/Removal of
𝛽-Amyloid in Alzheimer’s Disease
Role of Neuroinflammation. It is believed that A𝛽 is generated
continuously and its aggregation and subsequent plaque
deposition in AD is concentration-dependent. Excessive
accumulation of both soluble and insoluble A𝛽 may occur
not only as a result of aberrant APP processing by 𝛽- and
𝛾-secretase enzymes but may also be caused by inefficient
removal of newly generated A𝛽. Reduced activity of A𝛽-
degrading enzymes, such as neprilysin, insulin degrading
enzyme (IDE), and angiotensin converting enzyme I (ACE
I), may provoke an imbalance between the amyloid genera-
tion and clearance [13–19]. Additional predisposing factors,
including the ApoE status and the presence of comorbidities
such as metabolic syndrome and diabetes likely contribute to
sporadic AD in a manner, which is still poorly understood.
A lack of direct correlation between amyloid plaque
burden and memory loss in AD patients demonstrates that
neurotoxicity is not solely dependent on the insolubleA𝛽 [14–
16]. In fact, biochemical studies have demonstrated a good
correlation between the levels of soluble A𝛽 oligomers in
the brains of patients with AD and the degree of cognitive
impairment [19]. It has been suggested that solubleA𝛽-driven
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synaptic loss may be responsible for neurodegeneration
observed in AD. If that turns out to be the case, then central
nervous system (CNS) inflammatory processes will likely be
implicated [20, 21]. Neuroinflammation is a blanket term
used to describe immune response in neurodegenerative
diseases. It involves the activation of glial cells, especially
microglia and astroglia. Under physiological conditions,
microglial cells have a phagocytic function. In AD, activated
microglia secrete a large number of molecules [21–23]. Such
substances, among which are proinflammatory cytokines,
prostaglandins, reactive oxygen species (ROS), and nitric
oxide synthase (NOS), contribute to a chronic state of
perpetual stress. A prolonged release of all these factors can
eventually cause neuronal death [22, 23].
2.2. Antiamyloidogenic Pathway and Amyloidogenic Route as
Strategies for Development of Therapeutic Treatments Modify-
ing the Course of Alzheimer’s Disease. In the last two decades,
the pharmaceutical industry has focused primarily on the
amyloidocentric approach, devoting substantial resources to
develop effective AD drugs. However, multiple failures of
drug candidates in clinical trials have led researchers to
question the feasibility of this strategy [10–12]. One possible
reason for failure is a lack of biomarkers which could reliably
identify AD in relatively early stages. It is entirely possible
that the patients currently recruited for phase III trials are in
such advanced stages of AD that any attempted intervention
is probably useless. Therefore, new diagnostic tools capable
of early detection are sorely needed. In the meantime, there
is still a number of novel treatments under development,
which target the amyloidogenic route. In order to reduce A𝛽
generation from the APP, 𝛾- and 𝛽-secretase inhibition and
the potentiation of 𝛼-secretase activity have been considered.
Inhibitors and Modulators of 𝛽-Secretase. 𝛽-secretase enzyme
complex participates in the initial stages of the amyloidogenic
APP-processing pathway. The development of 𝛽-secretase
inhibitors is a challenge because, besides the APP, this
complex has manymore substrates. To give just one example,
neuregulin-1, which is involved in the myelination of CNS
axons and synaptic plasticity, is a target of 𝛽-secretase [3].
Broad range of substrates can lead to significant side effects,
even if the specific inhibition of the enzyme is achieved.
Nevertheless, E2609 (clinical trial ID# NCT01600859), MK-
8931 (NCT01739348), and LY2886721 (NCT01807026 and
NCT01561430) have all shown efficacy in reducing A𝛽 pro-
duction by up to 80–90% in the cerebrospinal fluid (CSF)
in humans. None of 𝛽-secretase inhibitors have reached the
market so far [3, 24–27].
Inhibitors and Modulators of 𝛾-Secretase. The 𝛾-secretase
complex is responsible for the final stage of amyloidogenesis,
leading to the generation of A𝛽(1-40) and A𝛽(1-42). 𝛾-
secretase inhibition was initially considered a promising
disease-modifying strategy. However, substrate promiscuity
presents similar issues facing 𝛽-secretase inhibitors [28–30].
Notch protein, responsible for regulating cell proliferation,
development, differentiation, and cellular communication,
is one of the targets of the 𝛾-secretase [28]. Just as with
the 𝛽-secretase inhibitors, off-target secondary effects are a
major concern [30].
Semagacestat (LY450139) is a 𝛾-secretase inhibitor that
decreased A𝛽 levels in blood and CSF in humans [31].
The clinical study results, (NCT00762411, NCT01035138, and
NCT00762411) which recruited over 3000 patients, are an
example of the worst possible outcomes. It was reported that
semagacestat treatment was associated with the worsening
of cognition and the abilities to carry out the activities of
daily living (ADAS-cog scale) in AD patients. Additional
side effects included weight loss, increased incidence of skin
cancer, and a higher risk of infection. Avagacestat is another
𝛾-secretase inhibitor the development of which was dis-
continued as a result of a lack of efficacy (NCT00810147,
NCT00890890, NCT00810147, NCT01079819) [32–34].
Selective 𝛾-secretase modulators (SGSM) may, in theory,
be developed in such a way as to avoid the adverse events
associated with general enzyme inhibition. The goal of such
treatments is to block APP processing without interfering
with other signaling pathways like Notch [35].
SGSM development began with the observation that
several nonsteroidal anti-inflammatory drugs (NSAIDs)
decreased A𝛽(1-42) peptide levels in vitro and in vivo. Exam-
ples of these drugs are ibuprofen, sulindac, indomethacin,
and flurbiprofen [36]. The accepted mechanism of action
(MOA) ofNSAIDs is the inhibition of cyclooxygenase (COX)
enzymes. While ibuprofen is a COX inhibitor, R-flurbiprofen
(Tarenflurbil) is not, and its effects on the reduction of
A𝛽 levels cannot be attributed to COX inhibition. Unfor-
tunately, Tarenflurbil and Ibuprofen did not show efficacy
for AD treatment in their respective clinical trials [36, 37].
CHF5074, just like R-flurbiprofen, is an NSAID devoid of
COX inhibitory activity. In vitro, CHF5074 inhibited A𝛽(1-
42) production presumably by blocking 𝛾-secretase com-
plexes [38–41]. Recent studies have reclassified this com-
pound as a microglial modulator based on its ability to
reduce both amyloid burden and microglial activation [39].
Results from a phase II trial in patients with Mild Cognitive
Impairment (MCI) indicate that CHF5074 treatment leads
to improvements of several cognitive measures and reduces
inflammatory marker levels in the CSF [38–40].
The idea that the long-term use of NSAIDs could confer
some protection against AD generated some interest in
NSAIDs as a treatment potentially useful for reducing A𝛽(1-
42) levels. However, negative results reported in clinical trials
with NSAIDs suggest that this hypothesis requires further
refinement [37].
Another example of a possible SGSM is NIC5-15, which
is a naturally occurring molecule. NIC5-15, also known as
pinitol, is a natural cyclic sugar alcohol [41]. This compound
supposedly modulates 𝛾-secretase and is reportedly capable
of reducing A𝛽 production, while not affecting the substrate
cleavage of Notch. No peer-reviewed data are available for
this compound, so any reported results should be considered
as a forward-looking statements requiring rigorous scientific
proof. However, it is claimed that the compound improves
cognitive function and memory in preclinical models of AD
neuropathology. If true, these data suggest that NIC5-15 may
be a suitable therapeutic agent for the treatment of AD for
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two reasons: (a) it preserves Notch activity and (b) also it is
potentially an insulin sensitizer. Moreover, it is supposedly
being investigated as an anti-inflammatory inhibitor because
it may preventmicroglia activation. Once again, independent
researchers have not yet confirmed these results.
2.3. Inhibition of 𝛽-Amyloid Peptide Aggregation. A𝛽 pep-
tide aggregates give rise to amyloid plaques. The following
compounds were developed in order to prevent senile plaque
formation.
The only inhibitor of A𝛽 aggregation that reached phase
III trials is the 3-amino-1-propaneosulfonic acid (3-APS, Alz-
hemed, tramiprosate) [42, 43].This medication was designed
to interfere with or antagonize the interaction of soluble A𝛽
with endogenous glycosaminoglycans. Glycosaminoglycans
have been shown to promote aggregation of A𝛽 amyloid fibril
formation and deposition [43]. However, the disappointing
results of the phase III clinical trial in 2007 have led to the
suspension of this compound in Europe [44].
Colostrinin, a complex of proline-rich polypeptides
present in ovine, bovine, and human colostrum inhibits
aggregation of A𝛽 and its neurotoxicity in cell assays,
and improves cognitive performance in mice models [45].
Although a phase II trial showed slight improvements inMini
Mental State Evaluation in patients with mild AD in a treat-
ment period of 15months, this beneficial effect was notmain-
tained after another 15 months of continuous treatment [45].
Scyllo-inositol (ELND005) is an oral amyloid antiaggre-
gation agent capable of reducing A𝛽 toxicity in the mouse
hippocampus. 18-month long phase II clinical trial with
ELND005 was conducted in participants with mild-to-
moderate AD. This dose-finding, safety and efficacy trial did
not meet its primary clinical efficiency outcomes [46].
Clinical trials for AD treatment were also performedwith
metal chelating 8-hydroxiquinolines (8-HQ) compounds
clioquinol and PBT2 [47].While theirmechanism of action is
not completely understood, it is thought that these molecules
block the interaction between the base metals and brain A𝛽
peptide. It was suggested that increased levels of oxidative
stress in the brain of AD patients might be partially due to
copper ions binding to A𝛽, leading to metal-mediated gen-
eration of reactive oxygen species (ROS) [48–50]. It was also
hypothesized that 8-HQs may prevent A𝛽 aggregation while
simultaneously restoring homeostasis in cellular levels of
copper and zinc ions [49, 50]. Unfortunately, these molecules
failed in the phases II and III of clinical development due to
lack of efficacy.
2.4. Compounds Which Promote the Removal of Amyloid
Deposits and Aggregates. Another potential treatment option
which is centered on the amyloidogenic pathway is to pro-
mote the clearance of existing amyloid aggregates and
deposits. To achieve this, three different strategies have been
evaluated.
2.4.1. Activation of Enzymes That Degrade Amyloid Plaques.
Aggregates and amyloid plaques are degraded by multiple
proteases including neprilysin, IDE, plasmin, endothelin
converting enzyme, angiotensin converting enzyme, and
metalloproteinases. Protein levels of these enzymes decrease
in AD, which contributes to the formation and accumula-
tion of A𝛽 [13–16]. Despite being an attractive strategy for
developing disease-modifying drugs, no compounds with
this MOA have ever reached advanced clinical development
due to the lack of specificity.
2.4.2. Modulation of 𝛽-Amyloid Transport between the Brain
and the Peripheral Circulation. A𝛽 transport between the
CNS and the peripheral circulation is regulated by (1)
apolipoproteins (e.g., A𝛽may be transported from the blood
to the brain when it is bound to APOE); (2) low-density
lipoprotein receptor-related protein (LRP-1), which increases
A𝛽 outflow from the brain to the blood; (3) receptor for
advanced glycation end products (RAGE), which facilitates
the transport of A𝛽 across the blood-brain barrier (BBB)
[15, 51, 52].
The goal of any treatment, which is focused on this mech-
anism, is to reduce cerebral amyloid load by attempting
to restrict A𝛽 to the peripheral circulation. To this end, a
number of different strategies have been proposed, notably
the peripheral administration of LRP-1. However, the only
drug candidates that have reached clinical stage are the inhib-
itors/modulators of RAGE. These include PF-0449470052,
which failed in phase II trials, and TTP4000, with the phase I
trial completed in February 2013 (NCT01548430).The results
of this trial have not been published.
2.4.3. Antiamyloid Immunotherapy
Active Immunotherapy. Immunotherapy strategy aimed to
promote A𝛽 clearance with the objective of reducing the
amyloid load in AD. Active immunization (vaccination) with
either A𝛽(1-42) (predominant form found in senile plaques)
or other synthetic fragments has been successfully evaluated
in transgenicmousemodels ofAD.Assays are generally based
on the stimulation of B cells, T cells, and immune responses
through activation of the phagocytic capacity of microglia.
Human tests were initially promising; however treatment
with the first-generation vaccine (AN1792) has produced
serious adverse events that led to the discontinuation of the
phase II trial. AN1792 consisted of a synthetic full-length
A𝛽(1-42) peptide with a QS-21 adjuvant. As a result of a
T cell-mediated autoimmune response, 6% of patients have
developed cerebral inflammation which turned out to be
aseptic meningoencephalitis [53].
Second-generation vaccines were designed using a
shorter A𝛽(1-6) peptide segment in an attempt to prevent
nonspecific immune response seen with the full-length
vaccine. CAD 106, designed byNovartis, was the first second-
generation vaccine that reached the clinical phases of devel-
opment [54]. A recently completed phase II clinical trial have
shown a A𝛽-specific antibody response in 75% of treated
patients, without causing adverse inflammatory reactions.
ACC-001, developed by Janssen, has recently completed two-
phase II trials (NCT01284387 and NCT00479557) with an
additional phase II trial still ongoing (NCT01227564). How-
ever, the pharmaceutical company has abandoned the plans
for further development of this vaccine. Other vaccines,
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including tetra-palmitoylated A𝛽(1-15) reconstituted in a
liposome (ACI-24), MER5101 and AF205 are currently in
various stages of preclinical development [55–58].
Passive Immunization. It is the administration of monoclonal
or polyclonal antibodies directed against A𝛽. This therapy
consists of the intravenous administration of anti-A𝛽 anti-
bodies to the patient. An advantage of this strategy compared
to active immunization is that the proinflammatory T cell-
mediated immune reactions should not occur. Studies in
transgenic animals have shown that passive immunization
reduces cerebral amyloid load and improves cognition, even
when the amyloid plaque numbers are not significantly
reduced. This could be attributed to the neutralization of
soluble amyloid oligomers, which are increasingly recognized
to play a fundamental role in the pathophysiologic cascade of
AD.
Bapineuzumab and solanezumab are two monoclonal
antibodies that have reached advanced stages of clinical
development [59]. However, in 2012, two phase III clinical
trials had failed because of a lack of efficacy in patients
with mild-to-moderate AD. Both bapineuzumab and solan-
ezumab are humanized monoclonal antibodies against A𝛽(1-
6) and A𝛽(12-28), respectively [60, 61]. In case of bapineuz-
umab, significant reduction in brain amyloid plaques and
phosphorylated Tau in cerebrospinal fluid was reported.
However, the treatment failed to produce significant im-
provements of cognitive function. In a solanezumab trial,
infusions of 400mg of solanezumab or placebo were admin-
istered once a month for 80 weeks in patients with mild-
to-moderate AD. The results suggested that solanezumab
may improve cognition in mild AD; however statistical sig-
nificance was not achieved in that study [61]. Currently
solanezumab is in phase III trials in patients with AD
(NCT01127633 and NCT01900665) and in older individ-
uals who have normal thinking and memory function
but who may be at risk of developing AD in the future
(NCT02008357).
Another monoclonal antibody, gantenerumab, is being
investigated in people at risk of developing presenile AD
due to genetic mutations. NCT01760005 trial is still recruit-
ing participants and will determine the efficacy of both
gantenerumab and solanezumab in the prodromal disease
stages [62–64]. In parallel, two additional phase III trials of
gantenerumab in patients with mild AD (NCT02051608) and
prodromal AD (NCT01224106) are ongoing. Gantenerumab
is a fully human IgG1 antibody designed to bind with high
affinity to a conformational epitope on the 𝛽-amyloid fibres.
Microglia recruitment and ensuing phagocytosis will pre-
sumably lead to amyloid plaque degradation. Experimental
studies in transgenic mice support this hypothesis.
Crenezumab (MABT5102A) is a humanized monoclonal
antibody which uses IgG4 backbone [65]. A phase II clinical
trial to assess the safety and efficacy in patients with mild-to-
moderate AD (NCT01343966) was completed in April 2014,
although the results are not yet publicly available. The most
recent phase II trial aiming to evaluate the safety and efficacy
of crenezumab in asymptomatic carriers of E280A autoso-
mal-dominant mutation of PSEN1 commenced in November
2013 (NCT01998841).
Other monoclonal antibodies against A𝛽 developed so
far include PF-04360365 (ponezumab) which targets the free
carboxy terminal amino acids 33–40 of the A𝛽 peptide;
MABT5102A, which binds to A𝛽monomers, oligomers, and
fibrils with equally high affinity; GSK933776A, which is
similar to bapineuzumab in that it binds to the N-terminal
A𝛽(1-5). In addition, other passive immunotherapies mostly
in phase I clinical development include NI-101, SAR-228810,
and BAN-2401 [57, 58, 61–65].
Gammagard is a preparation of antibodies from human
plasma. Its safety for human use had been previously dem-
onstrated in certain autoimmune conditions. Gammagard
effects were evaluated in a small number of AD patients
(NCT00818662). It is believed that this mixture contains a
small fraction of polyclonal antibodies against the A𝛽 pep-
tide. In addition, this preparation may possess immunomod-
ulatory properties that could potentially enhance microglial
phagocytosis [66–68].
3. Strategies Focused on Tau Proteins
Tau proteins are highly soluble and abundant in the neurons
where they play a critical role in microtubule stabilization,
particularly in axons [69–71]. Tau hyperphosphorylation
leads to the formation of insoluble paired helical filaments
(PHF) which form neurofibrillary tangles. The loss of micro-
tubule-binding capacity provokes cytoskeleton destabiliza-
tion, which eventually causes neurodegeneration and neu-
ronal death [70]. As an alternative to amyloidocentric
approaches, Tau-centered treatments aim to inhibit the phos-
phorylation and/or aggregation of Tau protein. In addition,
microtubule-stabilizing drugs could be used as a disease-
modifying strategy in AD [71]. In recent years, immunomod-
ulation was suggested as a viable option for promoting
effective clearance of Tau aggregates.
3.1. Inhibitors of Tau Hyperphosphorylation. All Tau proteins
are a product of alternative splicing of a microtubule-asso-
ciated protein Tau (MAPT) gene. Phosphorylation is the
primary mechanism which regulates Tau binding to micro-
tubules. Under physiological conditions the protein remains
soluble; however, in AD, pathological hyperphosphorylation
of Tau compromises its normal functions [72, 73]. Hyper-
phosphorylation occurs as a result of an imbalance between
the catalytic activity of kinases and phosphatases. Increased
expression of active forms of various kinases in the areas
proximal to neurofibrillary tangles has been described in
AD, including CDK5, GSK3𝛽, Fyn, stress-activated protein
kinases JNK and p38, and mitogen-activated protein kinases
ERK1 and ERK2 [74]. Some or all of these kinases con-
tribute to the perpetuation of the phosphorylation of Tau
in neurofibrillary tangles [73, 75–81]. As a result, significant
research efforts have been devoted to the development of
kinase inhibitors as a possible treatment strategy for AD. For
example, SP600125, a widely used pan-JNK inhibitor, exerts
beneficial effects on cognition and reduces neurodegenera-
tion in an APP/PS1 transgenic mouse model of AD [80]. It
has been proposed that specific inhibition of JNK3 could be
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sufficient to bring similar benefits as seen with SP600125 in
rodent models [78–81]. Human data in AD patients indicate
a positive correlation between the levels of JNK3 and A𝛽(1-
42) in the brain [77]. Furthermore, JNK3 upregulation was
detected in the CSF and was associated with memory loss.
Thus, JNK3 inhibition remains a promising target for future
therapies [81].
CDK5 belongs to the family of serine/threonine cyclin-
dependent kinases and is responsible for a number of phys-
iological functions within the CNS, including neurite out-
growth and the regulation of axonal development [82]. CDK5
catalytic activity is dependent on its direct association with
p35, key regulator of CDK5 signaling.This cofactor is cleaved
by a nonlysosomal protease calpain in a calcium-dependent
manner [83]. Conversion of p35 to p25 results in prolonged
activation and mislocalization of CDK5. Due to the increases
in intracellular calcium levels observed in the brains of AD
patients, pathological activation of CDK5 occurs, resulting
in hyperphosphorylation of Tau and neuronal cell death
[83, 84]. CDK5 inhibition may thus also be potentially
considered as a possible drug target. Currently existingCDK5
inhibitors roscovitine and flavopiridol have demonstrated
neuroprotective properties in in vitro and in vivo models of
excitotoxicity, ischemia, and neurodegeneration [84, 85].
GSK3𝛽 inhibitors are arguably in the most advanced
stages of clinical development for AD. Among the various
drugs that are currently being studied, tideglusib, an irre-
versible inhibitor of GSK3𝛽, has recently completed phase
II trials (NCT01350362). Tideglusib administration for a
period of 26 weeks to patients with mild-to-moderate AD
did not show clinical efficacy, and the compound has since
been discontinued for this indication [86]. Another study
(NCT00948259) evaluated the safety and tolerability of a 20-
week administration of NP031112 compared with placebo in
patients with AD. No data has been reported for this study.
Phosphatase activation has also been considered as a
possible drug target. Currently, there is only one protein
phosphatase 2 (PP2A) agonist in development. Sodium
selenite (VEL015) is undergoing phase II trials in Australia
(ACTRN12611001200976). Experimental studies have shown
that sodium selenate reduces Tau phosphorylation, both
in cell culture and in mouse models of the disease [86–
88]. VEL015 administration to rodents have resulted in
significant cognitive improvements and substantial reduction
of neurodegenerative phenotype.
3.2. Inhibitors of Tau Aggregation. Hyperphosphorylated Tau
aggregates contribute to neurotoxicity observed in AD brain.
Methylene blue dye derivatives have shown some promise in
inhibiting the formation of Tau aggregates. Methylene blue
disrupts the aggregation of Tau, has the ability to inhibit amy-
loid aggregation, improves the efficiency of mitochondrial
electron transport chain, reduces oxidative stress, prevents
mitochondrial damage, and is also a modulator of autophagy
[74, 89]. The first-generation molecule derived from methy-
lene blue (Rember) appeared to stabilize AD progression in
a clinical trial which lasted 50 weeks. These results motivated
researchers to develop a next-generation version of methy-
lene blue, TRx 0237. This compound is a purified derivative
of methylene blue which not only inhibits Tau protein
aggregation but also dissolves brain aggregates of Tau [74].
Several clinical trials are currently underway (NCT01626391,
NCT01689233, NCT01689246, NCT01626378) to evaluate the
potential efficacy of this drug in AD.
3.3. Microtubule Stabilizers. Microtubule stabilization may
potentially achieve a similar end-result as that seen with
the inhibitors of Tau hyperphosphorylation and aggregation.
Paclitaxel is amicrotubule-stabilizing drug currently in use in
the oncology field. Unfortunately, this compound is incapable
of crossing the BBB and its use is associated with serious
adverse events, which limits its utility in AD [90, 91]. In addi-
tion to paclitaxel, other microtubule-stabilizing compounds
such as TPI 287 have been considered as a possible AD
therapy. TPI 287 is a derivative of taxane, also used in cancer
treatment. TPI 287 stabilizes the microtubules by binding
to tubulin. NCT01966666 clinical trial will evaluate TPI-
287 safety, pharmacokinetic properties, and tolerability by
intravenous infusion in mild-to-moderate AD.
Epothilone D is a microtubule-stabilizing compound
which improved axonal transport, reduced axonal dystrophy,
decreased Tau neuropathology, and reduced hippocampal
neuron loss; however, drug development for AD was discon-
tinued in 2013 after a failed clinical trial [91].
With respect to Tau, additional studies are necessary in
order to better understand the exact molecular mechanisms
involved in Tau neurotoxicity. Recent studies comparing the
neurotoxic profiles of various forms of Tau suggest that a sol-
uble form is likely the most toxic [69]. This has been corrob-
orated by a recent report specifically identifying oligomeric
Tau as toxic [92]. Therefore, future therapeutic strategies
should be focused on targeting soluble forms of Tau.
3.4. Anti-Tau Immunotherapy. Just as with the immunother-
apies targeting A𝛽, both passive and active immunization
approaches against Tau have been considered. In fact, it was
demonstrated that reductions in Tau aggregate formation
and improved clearance of Tau oligomers and insoluble
aggregates could all be achieved with either active or passive
immunotherapies [93]. In rodents, treatment with mono-
clonal antibodies directed against hyperphosphorylated Tau
has led to improvements in cognition and was not associated
with significant adverse effects [93].
In 2013 Axon Neuroscience began a phase I trial to
evaluate the safety and tolerability of AADvac-1, an active
immunotherapywhich consists of a synthetic peptide derived
from the Tau sequence coupled to keyhole limpet hemo-
cyanin; the precise molecular nature of the antigen has
not been disclosed (NCT01850238 and NCT02031198) [94].
AADvac-1 uses aluminum hydroxide as an adjuvant. At
the 2014 Alzheimer’s Association International Conference
(AAIC) in Copenhagen, good preclinical safety profile was
reported for the treatment period of up to 6 months in rats,
rabbits, and dogs. These early results are encouraging and
it remains to be seen whether AADvac-1 will demonstrate
acceptable safety and efficacy in human patients.
8 Neural Plasticity
4. The Cholinergic Hypothesis
AD is a neurodegenerative disease characterized by a pro-
gressive loss of learning and memory as well as neuronal
death. The hippocampus, the main brain region involved in
memory processing, is influenced by cholinergic modulation
[95]. One of the well characterized anomalies associated
with neurotransmitter alterations is the degeneration of
cholinergic neurons in the nucleus basalis of Meynert and
the loss of cholinergic inputs to the neocortex and hippo-
campus. Several studies reported decreases in choline acetyl-
transferase (ChAT), acetylcholine (ACh) release, as well as
reductions in nicotinic and muscarinic receptors in the
cerebral cortex and hippocampus of postmortem AD brains
[96]. Acetylcholinesterase inhibitors (AChEI), one of the only
2 classes of drugs currently approved for AD treatment, act by
increasing ACh bioavailability at the synapse. Unfortunately,
none of these drugs are capable of reversing the course of
AD nor of even appreciably slowing down the rate of disease
progression [97]. Their clinical effect is largely palliative;
however, their potential use in combination therapy with
other disease-modifying compounds should not be excluded.
Ladostigil (TV3326) is both a reversible inhibitor of
AChE and is a selective and irreversible inhibitor of brain
monoamine oxidases A and B, the use of which improves
extrapyramidal symptoms and provides an antidepressant
effect [98, 99]. It also appears to be a potent antiapoptotic,
antioxidant, anti-inflammatory, and neuroprotective agent.
NCT01429623 and NCT01354691 phase II clinical trials with
ladostigil are currently underway.
5. Dendritic Hypothesis
(A𝛽-PrPC–mGluR5–Fyn Signaling)
Dendritic abnormalities appear in the relatively early stages of
AD. While dystrophic neurites, reduced dendritic complex-
ity, and dendritic spine loss are all documented features of
AD, it is only recently that we are beginning to understand the
underlying molecular changes that occur on the postsynaptic
side, in the dendrite [100–102]. Some data suggest that soluble
A𝛽 oligomers are the principal neurotoxic species responsible
for dendritic pathology. A𝛽 oligomers may cause aberrant
N-methyl-D-aspartate receptor (NMDAR) activation post-
synaptically by forming complexes with the cell-surface
prion protein (PrPC). PrPC is enriched at the neuronal
postsynaptic density, where it interacts with Fyn tyrosine
kinase-metabotropic glutamate receptor 5 complex (Fyn-
mGluR5). Fyn activation occurs when A𝛽 is bound to PrPC-
Fyn-mGluR5 complex. Activated in this manner, Fyn can
cause tyrosine phosphorylation of the NR2B subunit of this
NMDAR.This results in an initial increase and then a loss of
cell-surface NMDARs [103]. Fyn overexpression accelerated
synapse loss and the onset of cognitive impairment in the J9
(APPswe/Ind) transgenic AD mouse model, while its inhibi-
tion produced an opposite effect [100]. In addition, as men-
tioned earlier, Fyn can also contribute to Tau hyperphospho-
rylation. Previous studies had reported elevated levels of Fyn
in AD brain. Furthermore, Fyn was shown to phosphorylate
Tau at Tyr18 residue [101]. Thus, Fyn appears to be a viable
target in the treatment of AD pathology. Saracatinib
(AZD0530) and masitinib (AB1010) are Fyn kinase inhibitors
currently in phase II and phase III clinical trials for mild-to-
moderate AD (NCT01864655, NCT02167256, NCT00976118,
NCT01872598) [103–105]. Both compounds are capable of
blocking Fyn in a nanomolar range.
In a NCT00976118 clinical trial, oral masitinib was
administered for a period of 24 weeks, concomitantly with
one of the AChEIs (donepezil, rivastigmine, or galantamine)
and/ormemantine. In that study a significant improvement in
the ADAS-Cog test response was reported. These results are
encouraging; however, the very small patient pool (𝑛 = 26)
on memantine in this phase II trial is clearly not sufficient to
draw conclusions on the potential efficacy of this compound.
MOAofmasitinib inAD is twofold. Apart fromblocking Fyn,
masitinib is also a stem cell factor (SCF) receptor (c-KIT)
inhibitor. By inhibiting SCF/c-Kit signaling on mast cells
(MCs), this compound may prevent neuroinflammation by
blocking the activatedMCs-microglia interactions [102–105].
6. 5-HT6 Receptors in Alzheimer’s Disease
5-HT6 receptors are expressed in areas of theCNS involved in
learning andmemory.Their inhibitionwas shown to promote
acetylcholine release. In AD, 5-HT6 antagonism may lead to
the restoration of acetylcholine levels [106]. This hypothesis
is supported by evidence that the 5-HT6 receptor antisense
oligonucleotides improve spatial learning andmemory in the
Morris water maze test in normal rats [107]. 5-HT6 inhibitors
may be useful in combination therapy, together with AChEIs.
For example, Lu-AE-58054 (SGS-518) andPF-05212365 (SAM-
531) are being considered as possible treatments for mild-to-
moderate AD. Other compounds that are in various stages of
clinical research are SUVN-502, AVN-322, and PRX-07034
[108].
7. Changing the Concept:
AD as a Metabolic Disorder
Clinical studies suggest that diabetes is a major risk factor
that contributes to AD pathology. Results from published
research indicate that there is a close link between insulin-
deficient diabetes and cerebral amyloidosis [109]. Peripheral
and central insulin signaling impairments are likely present
in both diseases. As a result, “type 3 diabetes” hypothesis of
AD was developed, which attempts to bridge the observed
metabolic phenotypes present in diabetes and AD into a
coherent framework. Insulin hormone is at a centerpiece of
this hypothesis [110].
Observationsmade in the “Hisayama Study” indicate that
altered expression of genes related to diabetes mellitus in AD
brains may be a result of AD pathology and suggest that
peripheral insulin resistance, metabolic syndrome, and/or
full-blown diabetesmay lead to worsening of cognitive symp-
toms [111]. Impaired central insulin signaling in the hippo-
campal circuits, a key region involved in learning and mem-
ory, is likely present in AD [112]. Glucose toxicity, insulin
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resistance, oxidative stress, elevated levels of advanced glyca-
tion end products, and cytokine-mediated neuroinflamma-
tion are among the proposed mechanisms by which diabetes
could increase the risk of AD development. In a recent
study, Clarke and colleagues demonstrated that hypothalamic
administration of soluble A𝛽 oligomers initiates neuroin-
flammatory cascades which eventually cause disturbances in
peripheral glucose homeostasis [113]. Tumor necrosis factor𝛼
(TNF𝛼) quite possibly plays an important role in this process
[114, 115].
As molecular mechanisms causing AD and T2DM
pathologies are possibly related, it is logical to assume that
drugs used in T2DM treatment may have a neuroprotective
effect in AD [116].Thiazolidinediones (TZDs) are an example
of antidiabetic compounds whose possible role in AD was
investigated. TZDs are agonists of peroxisome proliferator-
activated receptor 𝛾 (PPAR-𝛾), which act by promoting
PPAR-𝛾 heterodimerization with the retinoid X receptor
(RXR). PPAR-𝛾/RXR heterodimer is a transcription factor,
which regulates expression of genes involved in lipid and
glucose metabolism. TZDs improve insulin sensitivity and
reduce cytokine-dependent inflammation [117, 118]. Rosigli-
tazone and pioglitazone are used as antidiabetic drugs,
which regulate glucose homeostasis by increasing insulin
sensitivity, reducing blood glucose levels, and improving
lipid metabolism. Both compounds have also been studied
as potential therapeutics for AD treatment, with reported
improvements in mitochondrial oxidative metabolism. In
animal models, pioglitazone modified various indices of
brain aging but did not slow down the cognitive decline [118].
Rosiglitazone and pioglitazone also induce the expression
of peroxisome proliferator-activated receptor-𝛾 co-activator 1
alpha (PGC-1𝛼), a molecule that plays multiple roles in mito-
chondrial biogenesis, energy metabolism, andmitochondrial
antioxidants expression. Previous studies have demonstrated
that, in the human brain tissues, the expression of PGC-
1𝛼 decreases with progression of AD dementia [119]. Thus,
PGC-1𝛼 upregulationmay improve themitochondrial energy
metabolism and AD pathology [120].
Pioglitazone treatment improved memory and cognition
in patients with mild-to-moderate AD in a small clinical trial
[121]. A larger phase II trial demonstrated improvements in
memory retention and attention with rosiglitazone treatment
(6 months) in patients who did not possess an ApoE4 allele
[122]. However, phase III trial using rosiglitazone failed to
show efficacy in AD (NCT00550420) [123]. It is important
to note that in these trials rosiglitazone was administered
alone at dosages that were much lower than those needed
to exert a beneficial effect on AD pathophysiology in rodent
models of the disease. NCT00348140 is a recently completed
clinical trial in which rosiglitazone was administrated in
combination with AChEIs in patients with mild-to-moderate
AD. No results have yet been reported.
Intranasal insulin had also been considered as a treatment
option for AD. This particular route of administration is
attractive as it bypasses the BBB. This is very significant
because insulin transport to the brain from the periphery
is dependent on active transport mechanisms which may
become disrupted in AD. In addition, the probability of
possible adverse events in peripheral tissues is minimized.
In theory, insulin delivery directly to the brain will acti-
vate cerebral insulin signaling leading to improvements in
memory processing and will result in neuroprotection [124,
125]. A currently ongoing clinical trial NCT01767909 is eval-
uating long-term (12 months) efficacy of intranasal insulin
(Humulin R U-100) in mild AD.
Other pancreatic hormones such as amylin may also play
a role in AD. Adler and colleagues reported that patients with
AD have reduced concentrations of plasma amylin. In trans-
genic animal models of AD, amylin and pramlintide (amylin
analog) decreased brain A𝛽 levels and improved cognition.
Interestingly, amylin also inhibited𝛽-secretase enzyme, while
pramlintide did not [126, 127].
8. Future Strategies
AD is a complex multifactorial disorder which may require
equally complex approaches to treatment. Early disease
detection, combination therapies, and lifestyle choices are
all likely contributors to the successful eradication of the
pathology (Figure 1) [128–132]. A broad range of studies show
that inadequate nutrition can increase the risk of disease
development [131]. A healthy diet can certainly improve
your chances of not developing AD. However, neither the
Mediterranean-type diet, caloric restriction, nor antioxidant
diet alone can prevent or delay AD. We believe that carefully
developed nutrition regimens coupled to combination phar-
macotherapies targeting multiple pathways involved in AD
are a way forward.
Biomarker identification, indicative of prodromal stages
of AD, can lead to early diagnosis and improve prognos-
tic outcomes. Currently existing diagnostic approaches are
focused on the detection of A𝛽(1-42) and total and phos-
phorylated Tau levels in the CSF and in the brain. Imaging
techniques such as brain MRIs are also used [133–135]. As
both A𝛽 and Tau increases likely appear when the disease
had already taken hold, we would welcome the discovery of
diagnostic markers which could predict the likelihood of AD
development at earlier stages.
Growth factors (GFs) are yet another set of molecules
which can potentially improve AD pathology. Transforming
growth factor 𝛽 family, insulin-derived GFs (insulin-like
growth factor 1, IGF-1 and insulin-like growth factor 2, IGF-
2), basic fibroblast growth factor (bFGF), and neurotrophins
(nerve growth factor, NGF; brain-derived growth factor,
BDGF; glial-derived neurotrophic factor, GDNF) all partic-
ipate in neurogenesis and neurodevelopment and may be
considered as potential targets for AD treatment [135, 136].
9. Concluding Remarks
In summary, accumulated evidence suggests that AD neu-
ropathology shows a multifactorial nature and involves
multiple biological pathways. Amyloid cascade hypothesis
has dominated the field for over 20 years, as a result of
which a large number of studies have focused on inhibition
and removal of A𝛽 and senile plaques. Unfortunately, the
amyloidocentric approaches have failed to demonstrate
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Figure 1: Future strategies in the treatment of late-onset and sporadic forms of AD could be centered on three main points: avoidance of
habits and lifestyle leading to obesity and diabetes; early detection of AD biomarkers or structural alterations in presymptomatic individuals;
and combined therapies in early phases of cognitive loss.
improvements in cognition in patients. Dendritic spine
defects clearly contribute to cognitive decline observed in
AD. These defects are considered an early event in memory
circuit’s destabilization and should be taken into account
for future development of investigational drugs. Novel phar-
macotherapies should not be limited to the postulates of
the amyloid cascade hypothesis. Events occurring at the
synapse may prove to be instrumental in understanding the
underlying pathology of this devastating disease.
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